- Home
- WIX vs NVCR Comparison
WIX vs NVCR Comparison
Compare WIX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WIX | NVCR |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | Israel | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2013 | 2015 |
Fundamental Metrics
Financial Performance| Metric | WIX | NVCR |
|---|---|---|
| Price | $80.11 | $17.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 6 |
| Target Price | ★ $134.67 | $28.08 |
| AVG Volume (30 Days) | 1.5M | ★ 1.7M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $15.80 | $7.72 |
| Revenue Next Year | $13.21 | $6.74 |
| P/E Ratio | $28.86 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $40.00 | $9.82 |
| 52 Week High | $190.92 | $21.45 |
Technical Indicators
Market Signals| Indicator | WIX | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 75.07 | 56.76 |
| Support Level | $75.00 | $14.84 |
| Resistance Level | $81.44 | $18.48 |
| Average True Range (ATR) | 5.11 | 0.80 |
| MACD | 1.75 | 0.19 |
| Stochastic Oscillator | 99.76 | 81.33 |
Price Performance
Historical ComparisonAbout WIX Wix.com Ltd.
Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years, it has invested heavily and introduced its Wix Studio offering for partners, which are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.